Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India.
Sood A, Duseja A, Kabrawala M, Amrose P, Goswami B, Chowdhury A, Sarin SK, Koshy A, Hyland RH, Lu S, Camus G, Stamm LM, Brainard DM, Subramanian GM, Prasad M, Bhatia S, Shah SR, Kapoor D, Shalimar, Saraswat V. Sood A, et al. Hepatol Int. 2019 Mar;13(2):173-179. doi: 10.1007/s12072-019-09927-6. Epub 2019 Feb 21. Hepatol Int. 2019. PMID: 30790229 Free PMC article. Clinical Trial.
Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B.
Sarin SK, Sood A, Kumar M, Arora A, Amrapurkar D, Sharma BC, Konar A, Chawla YK, Jain RK, Nanda V, Kumar A, Hissar S, Lavate P, Lahoti D; National Collaborative Group on Hepatitis B, India. Sarin SK, et al. Among authors: sood a. Am J Gastroenterol. 2007 Jan;102(1):96-104. doi: 10.1111/j.1572-0241.2006.01006.x. Am J Gastroenterol. 2007. PMID: 17266689
Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
Sood A, Midha V, Hissar S, Kumar M, Suneetha PV, Bansal M, Sood N, Sakhuja P, Sarin SK. Sood A, et al. Among authors: sood n. J Gastroenterol Hepatol. 2008 Feb;23(2):203-7. doi: 10.1111/j.1440-1746.2007.05057.x. Epub 2007 Jul 20. J Gastroenterol Hepatol. 2008. PMID: 17645472 Clinical Trial.
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.
Manns M, Zeuzem S, Sood A, Lurie Y, Cornberg M, Klinker H, Buggisch P, Rössle M, Hinrichsen H, Merican I, Ilan Y, Mauss S, Abu-Mouch S, Horban A, Müller TH, Welsch C, Chen R, Faruqi R, Pedicone LD, Wedemeyer H. Manns M, et al. Among authors: sood a. J Hepatol. 2011 Sep;55(3):554-563. doi: 10.1016/j.jhep.2010.12.024. Epub 2011 Jan 13. J Hepatol. 2011. PMID: 21237227 Clinical Trial.
Survey of inflammatory bowel diseases in India.
Makharia GK, Ramakrishna BS, Abraham P, Choudhuri G, Misra SP, Ahuja V, Bhatia SJ, Bhasin DK, Dadhich S, Dhali GK, Desai DC, Ghoshal UC, Goswami BD, Issar SK, Jain AK, Jayanthi V, Loganathan G, Pai CG, Puri AS, Rana SS, Ray G, Singh SP, Sood A; Indian Society of Gastroenterology Task Force on Inflammatory Bowel Disease. Makharia GK, et al. Among authors: sood a. Indian J Gastroenterol. 2012 Dec;31(6):299-306. doi: 10.1007/s12664-012-0258-1. Epub 2012 Oct 17. Indian J Gastroenterol. 2012. PMID: 23073755
3,247 results